Navigation Links
Aureus Pharma Announces Date of 2008 Annual User Symposium
Date:7/2/2008

PARIS, July 2 /PRNewswire/ -- Aureus Pharma, a leading provider of knowledge management solutions to accelerate discovery in the life science industry, announced today that the Aureus Pharma 2008 User Symposium will be held in Paris on October 23rd and 24th.

This symposium follows last year's highly successful inaugural event which was attended by many of Aureus' pharmaceutical and biotech customers from both Europe and North America. The symposium included presentations from industry scientists who described their experience and value perception of Aureus' solutions as applied to their discovery research projects. In addition, challenges and requirements for future developments were discussed.

At the 2008 event, Aureus will introduce several new products and services as well as provide users and prospective users with a better understanding of how Aureus technology can be beneficially implemented within their individual organizations.

"The first Aureus Pharma User Symposium was a great opportunity for our customers to discuss and share the benefits of their respective experiences related to knowledge driven discovery," said Jason Theodosiou, President & CEO of Aureus Pharma. "I am looking forward to this year's meeting as a continued dialog to direct and to improve Aureus Pharma's contribution to the life science industry."

For more information regarding Aureus Pharma's 2008 User Symposium, please visit http://www.aureus-pharma.com

About Aureus Pharma

Aureus Pharma headquartered in Paris, France is a privately held knowledge management based solutions provider for the life sciences industry. Aureus Pharma accelerates new drug discovery by providing knowledge databases which contain high quality quantitative information for both chemistry and biology. Researchers gain rapid access to knowledge for important drug target classes including GPCR, Ion Channel, Kinase as well as other critical pharmaceutical topics including ADME/Drug-Drug Interactions and the hERG Channel. The information contained in the Aureus Pharma system is of primary importance to aid in lead discovery and optimization as well as to build predictive models. For further information on how Aureus Pharma helps researchers turn data into discovery visit http://www.aureus-pharma.com

Media Contact

Mary Donlan

Director of Marketing

Aureus Pharma

Phone : +33-1-40-18-57-59 / +33-6-76-19-51-77

mary.donlan@aureus-pharma.com


'/>"/>
SOURCE Aureus Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. QSB Anti-Virulence Platform Inhibits Biofilm Formation by Staphylococcus Aureus MRSA and Candida sp
2. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
3. New ActivePure Technology Proven To Reduce Exposure to Methicillin Resistant Staphylococcus Aureus (MRSA)
4. WuXi PharmaTech (NYSE: WX) Appoints Mr. Bob Zhu as VP of HR
5. Addrenex Pharmaceuticals Licenses New Compound to Sciele Pharma for the Treatment of Hypertension and Other Potential Indications
6. CET Life Sciences Center Welcomes Belmont University School of Pharmacy as New Tenant
7. Pharmasset Joins Russell 3000 Index
8. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
9. Webcast Alert: Isis Pharmaceuticals Announces a Business Update Conference Call
10. Par Pharmaceutical Receives Final Approval to Market Generic Marinol(R) CIII (Dronabinol) Capsules
11. Alseres Pharmaceuticals, Inc. Raises $5 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology:
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):